These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

434 related articles for article (PubMed ID: 28475698)

  • 1. The Growing Need for Validated Biomarkers and Endpoints for Dry Eye Clinical Research.
    Roy NS; Wei Y; Kuklinski E; Asbell PA
    Invest Ophthalmol Vis Sci; 2017 May; 58(6):BIO1-BIO19. PubMed ID: 28475698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tear cytokine profile as a noninvasive biomarker of inflammation for ocular surface diseases: standard operating procedures.
    Wei Y; Gadaria-Rathod N; Epstein S; Asbell P
    Invest Ophthalmol Vis Sci; 2013 Dec; 54(13):8327-36. PubMed ID: 24204044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development and content validity assessment of the Dry Eye Disease Questionnaire in patients with dry eye disease, meibomian gland dysfunction, and Sjögren's syndrome dry eye disease.
    Sloesen B; Young A; Forde K; Hodson N; Bentley S; Walsh O; Naujoks C; O'Brien P; Sharma G
    J Patient Rep Outcomes; 2023 Jul; 7(1):64. PubMed ID: 37405617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Defining Dry Eye from a Clinical Perspective.
    Tsubota K; Pflugfelder SC; Liu Z; Baudouin C; Kim HM; Messmer EM; Kruse F; Liang L; Carreno-Galeano JT; Rolando M; Yokoi N; Kinoshita S; Dana R
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291796
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LipiFlow for the treatment of dry eye disease.
    Pucker AD; Yim TW; Rueff E; Ngo W; Tichenor AA; Conto JE
    Cochrane Database Syst Rev; 2024 Feb; 2(2):CD015448. PubMed ID: 38314898
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tear Proteomics Study of Dry Eye Disease: Which Eye Do You Adopt as the Representative Eye for the Study?
    Kuo MT; Fang PC; Kuo SF; Chen A; Huang YT
    Int J Mol Sci; 2021 Jan; 22(1):. PubMed ID: 33401599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tear Proteomics Approach to Monitoring Sjögren Syndrome or Dry Eye Disease.
    Kuo MT; Fang PC; Chao TL; Chen A; Lai YH; Huang YT; Tseng CY
    Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31010136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dry eye disease and proteomics.
    Jackson CJ; Gundersen KG; Tong L; Utheim TP
    Ocul Surf; 2022 Apr; 24():119-128. PubMed ID: 35278720
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular and cellular biomarkers in dry eye disease and ocular allergy.
    Enríquez-de-Salamanca A; Bonini S; Calonge M
    Curr Opin Allergy Clin Immunol; 2012 Oct; 12(5):523-33. PubMed ID: 22895048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dry eye disease: identification and therapeutic strategies for primary care clinicians and clinical specialists.
    Sheppard J; Shen Lee B; Periman LM
    Ann Med; 2023 Dec; 55(1):241-252. PubMed ID: 36576348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation Between the Inflammatory Marker HLA-DR and Signs and Symptoms in Moderate to Severe Dry Eye Disease.
    Brignole-Baudouin F; Riancho L; Ismail D; Deniaud M; Amrane M; Baudouin C
    Invest Ophthalmol Vis Sci; 2017 Apr; 58(4):2438-2448. PubMed ID: 28448672
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study design and baseline findings from the progression of ocular findings (PROOF) natural history study of dry eye.
    McDonnell PJ; Pflugfelder SC; Stern ME; Hardten DR; Conway T; Villanueva L; Hollander DA
    BMC Ophthalmol; 2017 Dec; 17(1):265. PubMed ID: 29284427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. sPLA
    Wei Y; Asbell PA
    Exp Eye Res; 2020 Dec; 201():108209. PubMed ID: 33011237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Role of Nano-ophthalmology in Treating Dry Eye Disease.
    Natesan S; Boddu SHS; Krishnaswami V; Shahwan M
    Pharm Nanotechnol; 2020; 8(4):258-289. PubMed ID: 32600244
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rethinking dry eye disease: a perspective on clinical implications.
    Bron AJ; Tomlinson A; Foulks GN; Pepose JS; Baudouin C; Geerling G; Nichols KK; Lemp MA
    Ocul Surf; 2014 Apr; 12(2 Suppl):S1-31. PubMed ID: 24725379
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The core mechanism of dry eye disease is inflammation.
    Wei Y; Asbell PA
    Eye Contact Lens; 2014 Jul; 40(4):248-56. PubMed ID: 25390549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding and Optimizing Ocular Biometry for Cataract Surgery in Dry Eye Disease: A Review.
    Nibandhe AS; Donthineni PR
    Semin Ophthalmol; 2023 Jan; 38(1):24-30. PubMed ID: 35989638
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.